Skip to main content
Diabetes, Metabolic Syndrome and Obesity logoLink to Diabetes, Metabolic Syndrome and Obesity
. 2020 Nov 3;13:4123–4129. doi: 10.2147/DMSO.S254883

Magnitude of, and Factors Associated with Cardiovascular Disease Among Type Two Diabetes Mellitus Patients

Adane Tesfaye 1, Haileyesus Josef 1, Temesgen Bizuayehu Wube 2,, Zeleke Girma 1, Belay Negasa 1, Temesgen Muche 1, Bewnetu Zewude 3
PMCID: PMC7649970  PMID: 33177852

Abstract

Background

Diabetes mellitus is becoming one of the major health problems in developing countries. The number of adults living with type 2 diabetes mellitus (T2DM) worldwide is increasing over time. Cardiovascular disease (CVD) is the major cause of death in T2DM. The objective of this study was to determine the prevalence of cardiovascular disease and its associated factors among diabetic patients at the MRC clinic of Dilla University Referral Hospital (DURH).

Methods

A hospital-based cross-sectional study was conducted from April to May 2019 . A total of 216 diabetic individuals were selected with a convenient sampling technique from patients on follow-up at DURH MRC. Data were collected using a structured format. The diagnosis of CVD was made with the necessary diagnostic tests and examination. The data analysis was done in SPSS software version 20. Bivariate and multivariable logistic regression analysis was carried out to identify factors associated with cardiovascular disease.

Results

A total of 216 patients participated in the study and the mean age of the study participants was 30 years; 83.3% of the study participants were male. The overall prevalence of cardiovascular disease was 25% of which 57% were ischemic heart disease, 32% were hypertensive and 10% were stroke. Duration of DM for more than 10 years and diabetic drug discontinuation were factors associated with cardiovascular disease. Odds of CVD was nearly four times more in those whose duration of DM is more than 10 years (AOR=4.00, 95% CI: 2.386–6.705) and odds of CVD among those who discontinued medication were almost three times more, (AOR=2.98, 95% CI: 1.287–6.080).

Conclusion

A quarter of the diabetic population studied developed CVD. Duration of DM for more than 10 years and drug discontinuation are independent associated factors of CVD. Hence appropriate intervention at early stages should be implemented at primary healthcare level.

Keywords: T2DM, cardiovascular disease, Ethiopia

Introduction

The International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM). People with diabetes comprise 8.8% of the world’s population, and the number of cases of diabetes is predicted to rise to 642 million by 2040.1,2 Individuals with T2DM and with chronically poor metabolic control can experience microvascular and macrovascular complications leading to a significant burden for the individual and for society. This burden includes direct costs of medical care and indirect costs, such as loss of productivity, which result from T2DM-related morbidity and premature mortality.3–5 Insulin resistance preceding long before the diagnosis of T2DM enhances atherogenic risk profile and has been delineated as a potential cause for subsequent increased risk of cardiovascular disease (CVD) among diabetic patients.6

Patients with T2DM disease are disproportionately affected by CVD compared with those without diabetes.7–10 CVD is a major cause of disability among people with T2DM2,11 and accounts for more than one-half of all the deaths due to T2DM.12,13 In persons with T2DM, the death rates were 15.4% for those with no prior myocardial infarction (MI) and 42.0% in patients having a history of MI which is in contrast with patients who did not have T2DM.10 Specifically, coronary artery disease (CAD) was most lethal, followed by stroke.14 A meta-analysis by Einarson et al. showed that atherosclerosis (29.1%) is the most prevalent CVD followed by CAD (21.2%) and heart failure (14.9%).15 Furthermore, diabetic patients with CVD have a worse prognosis for survival than CVD patients without T2DM and their quality of life also depreciates.

The elevated risk of cardiovascular events among diabetic versus non-diabetic patients emphasizes the need for screening of asymptomatic diabetic patients for CVD risk by the premise that earlier identification and stratification would lead to appropriate management of cardiovascular risk in both the long and short term.

There is a scarcity of comprehensive data on the prevalence and associated factors of CVD among patients with T2DM in Ethiopia, specifically in the study region. This study was therefore conducted to assess the prevalence of CVD and its associated factors among T2DM patients on follow-up at the diabetic clinic (MRC) of Dilla University Referral Hospital, Ethiopia.

Materials and Methods

Study Setting and Design

This was a hospital-based cross-sectional study conducted in Dilla University Referral Hospital, which is in Dilla Town, located 360 km away from the capital city, Addis Ababa, and 90 km from Hawassa in southern Ethiopia. Dilla University Referral Hospital serves a population of over 100,000 who are mainly (80%) rural. The hospital contains approximately 200 beds that provide surgical, gynecologic/obstetric, medical, and pediatric wards. It acts as a referral center for the surrounding primary healthcare units. The study period was from April to May 2019.

Study Population

The sample size was computed using a single population proportion formula, with the following assumptions: 95% confidence level to be 1.96, degree of precision (d) to be 0.05, and adding 10% for non-response yielding a sample size of 216. All selected adult diabetic patients who visited chronic medical outpatients department at Dilla University Referral Hospital during the study period made up the study population. Patients who were critically ill and unable to communicate during the interview were excluded.

Socio-Demographic and Clinical Data Collection

Socio-demographic data such as age, sex, residency and educational status, clinical data such as blood pressure and anthropometric related data of the study participants were collected using a structured questionnaire including a review of patients’ clinical records. Data were collected by face to face interview, followed by measurement of fasting blood glucose, blood pressure, height, and weight.

Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured from each subject with a standard adult arm cuff (sphygmomanometer). Two trained medical doctors who were working in the chronic diseases follow-up clinic measured the blood pressure from the right arm after a patient had rested for at least 5 minutes. The precision of the measurement was checked by using two readings two minutes apart and the average of the two readings was taken as blood pressure.

Diagnosis of CVD was made by the necessary diagnostic tests and examination. Anthropometric data (weight and height) were collected according to WHO guidelines. Weight was measured using a digital bath balance, Seca, which is a German model for weight measurement. A portable height measuring device with standing scale which was calibrated regularly against known weight and recorded to the nearest 0.1 kg was used. Body mass index (BMI) was calculated with the weight divided by the square of height in kilogram per meters square formula (BMI = weight/height2 in kg/m2). The patients were classified on the basis of body mass index (BMI) using WHO classification.16

Dyslipidemia was defined by the presence of more than one abnormal serum lipid concentration and hyperglycemia was defined as having fasting blood glucose level >110 mg/dL.

Data Processing and Analysis

Socio-demographic and economic data were cleaned manually and then entered into the computer using EPI Info version 7 and statistical analysis was carried out using SPSS version 20, with descriptive summary used to summarize the variable. Continuous variables such as age and income were first transformed into categorical variables before they were analyzed. First, the frequency of all the variables in the questionnaire was determined. Secondly, cross-tabulation was done between important variables, their significance was checked by bivariate analysis and multivariable logistic regression was done to assess the association of factors. Variables with a p-value of less than 0.2 in the bivariate analysis were entered into the final model. Important variables were entered and analyzed using multivariable logistic regressions to find factors associated with CVD among T2DM. Finally, the results of the study were presented using graphs and tables. In all cases, a p-value of <0.05 was considered statistically significant.

Results

Socio-Economic, Demographic and Other Characteristics

Out of the 216 study participants, the mean age of the study participants was 30 years and 126 (58.3%) were older than 30 years. Most 180 (83.3%) were male and 162 (75%) were urban residents. 36 (16.7%) had no formal education while 54 (25%) were degree holders. 72 (33.3%) were farmers and 90 (41.7%) earned more than 2500 birr and 126 (58.3%) were married (Table 1).

Table 1.

Socio-Demographic Characteristics of Diabetic Patients on Follow-Up at DURH, April to May, 2019

Variables Category Frequency Percent
Age <30 years 90 41.7
> 30 years 126 58.3
Total 216 100
Sex Male 180 83.3
Female 36 16.7
Total 216 100
Educational Status Uneducated 36 16.7
Grade 1–8 36 16.7
Grade 9 & above 18 8.3
Diploma 72 33.3
Degree 54 25
Total 216 100
Marital Status Married 126 58.3
Divorced 90 41.7
Total 216 100
Residency Urban 162 75
Rural 54 25
Total 216 100
Occupation Farmer 72 33.3
Employed 90 41.7
Jobless 54 25
Total 216 100
Income Less than 1000 birr 72 33.3
1000–2500 birr 54 25
More than 2500 birr 90 41.7
Total 216 100

About 90 (41.7%) were leading a sedentary life or were physically inactive and 38.5% were overweight (BMI >25). About 72 (33.3%) were cigarette smokers whereas 54 were khat chewers and another 54 (25%) were alcohol drinkers regularly.

Prevalence of CVD Among the Study Participants

The total prevalence of CVD among the study participants was 25% and 50% of the study participants were hypertensive. 41.7% had dyslipidemia and 16.7% had a family history of chronic illness. 33.3% had DM for more than 10 years and 33.3% of the study participants had diabetic drug discontinuation history (Table 2).

Table 2.

Clinical Characteristics of Diabetic Patients on Follow-Up at DURH, April to May, 2019

Independent Variables Frequency Percent
Ever Diagnosed with CVD? Yes 54 25.0
No 162 75.0
Total 216 100.0
Ever Diagnosed Hypertension? Yes 108 50.0
No 108 50.0
Total 216 100.0
Ever Diagnosed Dyslipidemia? Yes 90 41.7
No 126 58.3
Total 216 100.0
Past History Medical Illness Yes 36 16.7
No 180 83.3
Total 216 100.0
Family History of Chronic Illness Yes 36 16.7
No 180 83.3
Total 216 100.0
Duration of DM <5 years 90 41.7
5–10 years 54 25.0
More than 10 years 72 33.3
Total 216 100
Diabetic Drug Discontinuation History Yes 72 33.3
No 144 66.7
Total 216 100
IHD Yes 16 57
No 12 43
Total 28 100
HHD Yes 9 32
No 19 68
Total 28 100
Stroke Yes 3 10
No 25 90
Total 28 100

Abbreviations: CVD, cardiovascular disease; DM, diabetes mellitus; HHD, hypertensive heart disease; IHD, ischemic heart disease.

Factors Associated with CVD Among T2DM Patients

Age, occupation, family medical history of DM, alcohol drinking, drug discontinuation, duration of treatment, physical inactivity and obesity/overweight were found to be associated with CVD at bivariate level analysis. Drug discontinuation and duration of treatment for more than 10 years remained statistically significant at multivariable analysis level with 95% CI (AOR= 4.0, CI=2.0–8.0,P=0.02) and (AOR=3.0, CI=1.3–6.1, P=0.03) respectively. The odds of CVD among those who discontinued medication are four times more than those who did not discontinue their medication. The odds of CVD among those who were on DM treatment for more than 10 years is almost three times higher than those who were on treatment for less than 5 years (Table 3).

Table 3.

Bivariate and Multivariable Analysis of the Associations Between Selected Characteristics and the CVD Risk Factors in Diabetic Patients, DURH, April to May 2019

Variables Diagnosed CVD Total P-value AOR (95% CI)
Yes No
Age of Respondents
 > 30 years 18 108 126 <0.001
 <30 years 36 54 90 1
Residence
 Rural 0 54 54 1
 Urban 54 108 162 <0.001
Occupation
 Jobless 0 54 54
 Employed 36 54 90
 Farmer 18 54 72 <0.001
Family medical history (DM)
 No 54 126 180
 Yes 0 36 36 <0.001 2.3(1.7–3.2)
Duration of DM
 > 10 years 36 36 72 <0.001 4.0(2.4–6.7)* 3.0(2.0–8.0)**
 5–10 years 0 54 54
 <5 years 18 72 90
Diabetic drug discontinuation
 No 54 90 144
 Yes 0 72 72 0.003 2.0(1.4–2.8)* 2.8(1.3–6.1)**
Cigarette smoking
 Yes 54 90 144 0.001
 No 0 72 72
Khat chewing
 No 18 144 162
 Yes 36 18 54 <0.001
Alcohol drinking
 No 36 126 162
 Yes 18 36 54 <0.001 2.0(1.4–2.8)
Physical inactivity
 No 36 90 126
 Yes 18 72 90 <0.001 2.0(1.4–2.8)
Obesity
 No 36 108 144
 Yes 18 54 72 <0.001 2.0(1.4–2.8)

Notes: *P-value<0.2; **p-value <0.05.

Discussion

This study aimed to assess the prevalence of CVD and its associated factors among T2DM patients. 83.3% of the study participants were male and 75% of them resided in urban areas. 41.7% and 50% of the study participants had dyslipidemia and hypertension, respectively. The prevalence of CVD among the study participants is 25%. Duration of DM and unnecessary diabetic drug discontinuation are independent predictors of CVD among DM patients.

The prevalence of CVD among the study participants is 25% which is in agreement with reports from Cameroon (28.6%) and Southeast Asia (29.5%),17 but lower than reported in a systematic literature review on the prevalence of cardiovascular disease in T2DM, which revealed the highest prevalence of overall CVD in North America and the Caribbean (46.0%), Southeast Asia (42.5%) and the Western Pacific (including China) (33.6%).15 That review also reported a pooled prevalence of 32.2% of CVD.15 This difference could be due to the inclusion of diabetics under the age of 18 in the systematic review and differences in the study settings, study time, stage and types of overt complication of T2DM at which the data were collected. It also could be because of lifestyle differences of the study participants, which will be related with the each county’s development index as most of the studies included in the meta-analysis were from developed countries.

The high prevalence of CVD in the current study may cause increased morbidity and mortality among diabetic patients due to the synergism of hyperglycemia with other cardiovascular risk factors.18 The prevalence of dyslipidemia among the study participants was 41.7% which is relatively comparable with a follow-up study done on a Korean population (49.5%) and DIAB-CORE project (49.4%).19 The current studyresults were much lower than the study done in Durame general hospital, Ethiopia (65.6%),20 in Tanzania (94.1%)21 and Pakistan (95%).22 Another study also found dyslipidemia among hyperglycemic patients to be 92.4%.23 The high prevalence could be explained by genetic differences, difference in study setup or because of the method used to classify dyslipidemia.24,25

In the current study 50% of participants were hypertensive which is higher than the study done in southern Ethiopia (25.5%)26 and lower than the study done from DIAB-CORE project data (83.9%).19 The difference could be explained by a difference in lifestyle, study setup, genetics and mean age of the participants. We also cannot exclude cases of elevated blood pressure caused by the stress of the unfamiliar situation.

Duration of DM and unnecessary diabetic drug discontinuation are independent predictors of CVD among DM patients. This is because the longer duration of DM and drug discontinuation brought about hyperglycemia which is an important etiologic factor leading to complications of DM. The mechanism by which hyperglycemia leads to diverse cellular and organ dysfunction may be explained by hyperglycemia-induced increased production of reactive oxygen species or superoxide in the mitochondria causing different cytotoxicity in the cellular level and organ dysfunction.18

Limitation

The authors could not generalize the findings of the present study to the entire population as the current study was small in sample size and cross-sectional in study design. These findings need to be validated further through various epidemiological study designs, large sample sizes, and inclusion of various other socio-demographic and biological parameters. Moreover measurements of blood pressure and lipids based on a single testing opportunity provide evidence for the respective condition only.

Conclusion

A quarter of the diabetic population developed CVD. Duration of DM for more than 10 years and drug discontinuation are independent predictors of CVD.

Acknowledgments

Authors express their special thanks to all DM patients who took part in the study and all the staff of Dilla University Referral Hospitals, data collectors and supervisors who sacrificed their precious time for the success of this study.

Abbreviations

BMI, Body mass index; CVD, Cardiovascular disease; DM, Diabetes Mellitus; DURH, Dilla University Referral Hospital; HDL, High-density lipoprotein; HHD, hypertensive heart disease; IDF, International Diabetes Federation; IHD, ischemic heart disease; RBS, Random blood sugar; MRC, Medical referral clinic; MRFIT, Multiple risk factors intervention trials; WHO, World Health Organization.

Ethics Approval and Consent to Participate

This study was conducted in accordance with the Declaration of Helsinki. The study was approved by Dilla University, Internal Review Board. An official letter of cooperation was written from Dilla University College of Health Science to all concerned bodies. The aim, purpose, benefits and method of the study were clearly explained to the participants. The entire study participants had been informed that, the data obtained from them were used only for this study purpose, the confidentiality of the data were maintained and their names were not recorded. Next, the study participants was informed that they can withdraw from the study at any time and being withdrawn would not have any negative impact on their diagnosis and treatment in the hospital. Finally, each study participant had provided a signed consent before any data were collected.

Author Contributions

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

  • 1.Abraham TM, Pencina KM, Pencina MJ, Fox CS. Trends in diabetes incidence: the Framingham heart study. Diab Care. 2015;38:482–487. doi: 10.2337/dc14-1432 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels: International Diabetes Federation; 2015. [Google Scholar]
  • 3.American Diabetes Association. Economic costs of diabetes in the US in2007. Diabetes Care. 2008;31:596–615. doi: 10.2337/dc08-9017 [DOI] [PubMed] [Google Scholar]
  • 4.International Diabetes Federation. Diabetes Atlas, International Diabetes Federation Diabetes Atlas. 3rd ed. Brussels, Belgium; 2006. [Google Scholar]
  • 5.Bahia LR, Araujo DV, Schaan BD, et al. The costs of type ´ 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health. 2011;14:137–140. [DOI] [PubMed] [Google Scholar]
  • 6.Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care. 2009;32(2):361–366. doi: 10.2337/dc08-0854 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sarwar N, Gao P, Seshasai SR, et al. Diabetes Mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies emerging risk factors collaboration. Lancet. 2010;375:2215–2222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009;53(5):35–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Singh GM, Danaei G, Farzadfar F, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One. 2013;8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234. doi: 10.1056/NEJM199807233390404 [DOI] [PubMed] [Google Scholar]
  • 11.Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. doi: 10.1186/s12933-018-0728-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D’Agostino RB. The lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diab Care. 2008;31:1582–1584. doi: 10.2337/dc08-0025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(1):14–21. [DOI] [PubMed] [Google Scholar]
  • 14.Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol. 2009;8(1):53. doi: 10.1186/1475-2840-8-53 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. BMC Cardiovasc Diabetol. 2018;17(83):1–19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.World Health Organization. Diet, nutrition and prevention of chronic disease. Report of a joint WHO/FAO expert consultation. Tech Rep. 2003;916. [PubMed] [Google Scholar]
  • 17.Mareeswaran N, Savitha AK, Gopalakrishnan S. Prevalence of intestinal parasites among urban and rural population in Kancheepuram district of Tamil Nadu. Int J Community Med Public Health. 2018;5(6). doi: 10.18203/2394-6040.ijcmph20182199 [DOI] [Google Scholar]
  • 18.Harrison, the principle of internal medicine, 20th ED. 2018;20:3137–3142 [Google Scholar]
  • 19.Rückert I-M, Maier W, Mielck A, et al. Personal attributes that influence the adequate management of hypertension and dyslipidemia in patients with type 2 diabetes. Results from the DIAB-CORE Cooperation Cardiovascular Diabetology. 2012;11:120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Bekele S, Yohannes T, Eshete A. Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities, and People’s Region. Diabetes Metabol Syndr Obesity. 2017;10:265–271. doi: 10.2147/DMSO.S135064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nyasatu GC, Elichilia R, Tolbert S, Isaack AL. Lipid profile of Type 2 diabetic patients at a tertiary hospital in Tanzania: cross sectional study. J Endocrinol Diabetes. 2017;4(1):1–6. [Google Scholar]
  • 22.Sarfraz M, Sajid S, Ashraf MA. Prevalence and pattern of dyslipidemia in hyperglycemic patients and its associated factors among Pakistani population. Saudi J Biol Sci. 2016;23:761–766. doi: 10.1016/j.sjbs.2016.03.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Jayarama N, Reddy M, Lakshmaiah V. Prevalence and pattern of dyslipidemia in type 2 diabetes mellitus patients in a rural tertiary care centre, South India. GJMEDPH. 2012;1(3):24. [Google Scholar]
  • 24.Noh J, Han KD, Ko SH, Ko KS, Park CY. Trends in the pervasiveness of type 2 diabetes, impaired fasting glucose and co-morbidities during an 8-year-follow-up of nationwide Korean population. Sci Rep. 2017;7(46656):1–7. doi: 10.1038/srep46656 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol. 2012;10:684–686. doi: 10.2174/157016112803520864 [DOI] [PubMed] [Google Scholar]
  • 26.Woyesa SB, Hirigo AT, Wube TB. Hyperuricemia and metabolic syndrome in type 2 diabetes mellitus patients at Hawassa university comprehensive specialized hospital, South West Ethiopia. BMC Endocr Disord. 2018;17:76. doi: 10.1186/s12902-017-0226-y [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy are provided here courtesy of Dove Press

RESOURCES